Author: admin

Dr. Mark Kris of Memorial Sloan Kettering discusses phase II study of cabozantinib in RET rearranged NSCLC at the annual meeting in Chicago

This was my interview with Dr. Alok Khorana of the Cleveland Clinic at the ASCO Annual Meeting on May 30, 2015. Earlier that day, there was a presentation demonstrating significant benefit using pembrolizumab in patients with microsatellite unstable (MSI) tumors.

This is my conversation with Dr. Alok Khorana, Director of the GI Malignancy Program at the Cleveland Clinic. Dr. Khorana will be presenting an abstract Saturday, May 30, 2015 at the ASCO Annual Meeting on this research. He discusses incorporation of global oncology approaches to trials studying venous thrombemboli in GI cancers, and upcoming trials in this area.

Dr. Mark Kris, MD or Memorial Sloan Kettering discuss the role of BRAF mutations in NSCLC and the potential treatment with BRAF and MEK inhibitors.

Dr. Mark Kris, MD of Memorial Sloan Kettering discusses the Lung Cancer Mutation Consortium and the role of Next Generation Sequencing in NSCLC.

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Eleni Efstathiou (The University of Texas MD Anderson Cancer Center, Houston, TX) discusses prospective management strategies for prostate cancer. Topics of interest include radiotherapy, androgen-deprivation therapy (ADT), inhibitors of nuclear export and androgen-signalling inhibitors. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) summarises the status of poly (ADP-ribose) polymerase (PARP) inhibitors in preclinical and clinical development for the treatment of breast cancer. Prof. Dr. med. Fasching explains the design of the EMBRACA study, which is a 2:1 randomised phase 3 study comparing the efficacy and safety of the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universitä?t Erlangen-Nürnberg, Erlangen, Germany) discuss the functions of the BRCA1 and BRCA2 proteins in response to DNA damage in BRCA-related breast cancer. The development of molecular profiling in BRCA-related breast cancer has allowed an increasingly accurate assessment of tumour biology and should allow us to utilise this mutation in the treatment of the cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews what is known about the functions of poly (ADP-ribose) polymerase (PARP) and outlines the rational development of PARP inhibitors as anticancer agents for tumours associated with BRCA gene mutations. Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) describes targeting the defect in DNA repair in BRCA-related breast cancer with poly (ADP-ribose) polymerase (PARP) inhibitors. In BRCA-related breast cancer cells, DNA double-strand break repair is impaired, so inhibition of PARP, which has a role in DNA single-strand break repair, increases the susceptibility for additional DNA damage and cell death. Accordingly, PARP inhibitors may be important novel therapeutic agents for the treatment of BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews…

Michael Kolodziej, MD, National Medical Director, Oncology Strategies, Aetna, Inc. talks about Next Steps in Oncology Payment Reform for Established Provider & Payer Teams

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany) discuss the clinical development of the poly (ADP-ribose) polymerase (PARP) inhibitor, talazoparib, for the treatment of BRCA-related breast cancer. The ongoing EMBRACA study is a 2:1 phase 3 study comparing the efficacy and safety of the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Roberta L. Buell, Principal, OnPoint Oncology, LLC discusses the Top 2015 Reimbursement Issues & ICD-10 Update from the Coding Mistress

Robert Baird Jr., RN, MSA, Chief Executive Officer, Dayton Physicians Network discusses Payment Reform for Established Provider & Payer Teams

David Eagle discusses what Are the Key Cost Drivers of Cancer Care moving forward at the COA meeting in Orlando

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews the medical and social implications of BRCA gene mutation testing. Women with a deleterious BRCA gene mutation can be offered various management options, including prophylactic surgery and chemoprevention, to reduce the risk of breast cancer development. It is important for clinicians to understand and respond to a patients subjective experience during the clinical management process. This programme is supported by BioMarin Pharmaceutical European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

James W. Hodge, PhD, MBA, Investigator, Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Center talks about Perspective from the NCI: Importance of Immunotherapy Trials

Phil Johnson, MS, RPh, Director of Pharmacy (Retired), Moffitt Cancer Center talks about Biosimilar Overview: Opportunities & Issues

Jeff Mortier talks about the latest information about the Cancer Payment Reform Bill.

At the Myeloma 2015 meeting, Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Jesús San Miguel (University of Salamanca, Salamanca, Spain) and Prof Antonio Palumbo (University of Torino, Torino, Italy) on immunotherapies that are in clinical development for the treatment of multiple myeloma. Novel immune-based combinations that seem particularly noteworthy are discussed. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Gareth Morgan (University of Arkansas, Fayetteville, AR) and Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) on studies involving new tumour biology-guided strategies for treating multiple myeloma (MM). They focus on immune modulators and inhibitors of critical signalling pathways in MM. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Matti Aapro (Clinique de Genolier, Genolier, Switzerland) discusses the design and rationale of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey. The MAGIC survey is an evaluation of the heterogeneity of the treatment decisions made by clinicians regarding the need for adjuvant chemotherapy in breast cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Person they are interveiwng, their credentials

Bobbi Buell from onPoint Oncology talks about ICD-10 and what it means to oncology payments

Keith L. Knutson, PhD, Director, Cancer Vaccines and Immune Therapies Program, Vaccine & Gene Therapy Institute of Florida Practical Immuno-Oncology 101 for Oncologists & Nurses

Laura Stevens, Program Director for CMMI Come Home Project talks about the Come Home Project and how it works.

Ricky Newton of COA talks about the new COPA program called Community Oncology Pharmacy Association at the COA annual meeting in Orlando, FL.

Ted Okon and Peter Yu, MD discuss new legislative issues associated with oncology for 2015 at the COA annual meeting in Orlando, FL.

Bo Gamble & Carol Murtaugh talk about What does it take to become a Oncology Medical Home at the annual Community Oncology Alliance meeting in Orlando, 2015

On the first day of the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Jesús San Miguel (University of Salamanca, Salamanca, Spain) and Prof Antonio Palumbo (University of Torino, Torino, Italy) on new approaches for treating multiple myeloma (MM). Topics include early intervention for smoldering MM, treatment strategies for high-risk MM, and novel drugs in clinical development that may improve patient outcomes in MM. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) discusses the opportunities at the 14th St. Gallen International Breast Cancer Conference 2015 to develop new guidelines in breast cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Véronique Diéras (Institut Curie, Paris, France) discusses the phase 2 PALOMA-1 study of the cyclin-dependent kinase 4/6 inhibitor, palbociclib, in combination with letrozole versus letrozole alone as first-line treatment for women with oestrogen receptor-positive (ER+), HER2-negative (HER2-), advanced breast cancer. The addition of palbociclib to letrozole significantly improved progression-free survival in this patient population. A phase 3 trial is in progress. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Kidney Cancer Organization Welcome Lyon Meeting 2015 Carolyn Konosky

Kidney Cancer Meeting Lyon, France 2015: Immunotherapy versus targeted treatments in metastatic renal cell carcinoma:The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I

Kidney Cancer Meeting Lyon, France 2015: Functional imaging in renal cancer: a 10 year history. Tom Powles Barts Cancer Institute ECMC, UCH and Royal Free Hospitals: London Cancer Queen Mary University of London

Kidney Cancer Meeting Lyon, France 2015: Treatment beyond second line Camillo Porta Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy

Kidney Cancer Meeting Lyon, France 2015: Will Immunotherapy Marginalise Targeted Therapy to a Salvage Role by 2020? Tim Eisen University of Cambridge

Kidney Cancer Meeting Lyon, France 2015: Have Results of Recent Randomized Trials Changed the Role of mTOR Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France

Kidney Cancer Meeting Lyon, France 2015: What Have Sequencing Trials Taught Us?

Kidney Cancer Meeting Lyon, France 2015: Role of SBRT in the management of lung and liver metastases Ronan TANGUY, M.D. Radiation Oncologist

Kidney Cancer Meeting Lyon, France 2015: New target:FGFR & c-MET Laurence Albiges Gustave Roussy Institute, Dana-Farber Cancer Institute

Kidney Cancer Meeting Lyon, France 2015: 1st line treatment:what has changed in the last 2 years? Martin Gore PhD FRCP Royal Marsden Hospital Institute of Cancer Research London

Kidney Cancer Meeting Lyon, France 2015: LOCAL TREATMENT FOR LUNG ET LIVER METASTASES SURGERY/ABLATION IS THE GOLD STANDARD – Alain Ravaud, MD PhD Bordeaux University Hospital, Bordeaux, France

Kidney Cancer Meeting Lyon, France 2015: Toxicity from Checkpoint Inhibitors James LarkinFRCP PhD

Kidney Cancer Meeting Lyon, France 2015: TKI drug interaction: what else do I need to know for my patient for anti-VEGF? Romano Danesi, MD, PhD Professor of Pharmacology Department of Clinical and Experimental Medicine University of Pisa Medical School, Italy

Kidney Cancer Meeting Lyon, France 2015: Mechanisms and management of hypertension associated with anti-VEGF-treatment Stephane Ederhy Service de Cardiologie Hopital Saint Antoine Paris, France

Kidney Cancer Meeting Lyon, France 2015: Skin Side Effects Associated with Kidney Cancer Treatment Christiane Thallinger, MD University of Vienna, Department of Oncology, General Hospital vienna

Kidney Cancer Meeting Lyon, France 2015: Vaccines for RCC: Rationale and Clinical Update Hans Hammers M.D. / Ph.D. Assistant Professor: Medical Oncology, Chemical Therapeutics Johns Hopkins Kimmel Cancer Center

Kidney Cancer Meeting Lyon, France 2015: New Targets to Reverse VEGF Resistance Prof. Eric Raymond, MD, PhD Head of Medical Oncology UNIL-CHUV Lausanne – Switzerland

Kidney Cancer Meeting Lyon, France 2015: T-Cell Checkpoints in RCC:Musings from a non-immunologist Primo N. Lara, Jr., M.D. Professor of Medicine University of California Davis School of Medicine Associate Director for Translational Research UC Davis Comprehensive Cancer Center Sacramento, CA, USA